Information on the target
Sérélys Pharma is an internationally recognized player in the field of natural and non-hormonal solutions for women's health and well-being. With over fifteen years of experience, the company has developed scientifically validated products that address various women's health issues. Utilizing its patented "CyTonin" technology, Sérélys Pharma offers products derived from purified cytoplasmic extracts of carefully selected plant pollens. Its flagship product, Sérélys Meno, serves as a significant alternative to hormonal treatments for menopause-related disorders.
In addition to its primary offering, Sérélys Pharma has a diverse portfolio that includes solutions for urinary discomfort, premenstrual comfort, and bone health maintenance. The company generates nearly €20 million in revenue, with a quarter of its sales occurring in France, another quarter in the United States, and the remaining half distributed across approximately fifty countries in Europe and Asia.
Industry overview in the target’s specific country
The women's health market in France is experiencing significant growth, driven by increasing awareness and demand for non-hormonal treatment options. As societal attitudes towards women's health evolve, there is a growing recognition of the importance of addressing hormonal changes and their associated symptoms. This shift is particularly evident among women over the age of 45, with studies indicating that 80% of this demographic experience menopause-related symptoms.
Moreover, the French healthcare landscape is characterized by a robust regulatory framework that supports the introduction of innovative health solutions. The government and healthcare providers are increasingly focused on promoting preventive care and wellness, which aligns with the offerings of companies like Sérélys Pharma. This environment presents a favorable backdrop for the growth of natural health products, especially those that cater to women's specific health needs.
In addition, the rise of e-commerce and digital health platforms has transformed how women access health information and products. This trend has enabled companies to reach a broader audience and engage with consumers directly, further enhancing market opportunities. As a result, the demand for effective, safe, and scientifically backed solutions is on the rise, positioning Sérélys Pharma well within this expanding market.
The rationale behind the deal The acquisition of Sérélys Pharma by UPSA represents a strategic move to diversify UPSA's portfolio and strengthen its position in the women's health segment. By integrating Sérélys Pharma's innovative product offerings, UPSA aims to leverage its establishe…